Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 10× Ginkgo Bioworks Holdings Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | DNA | |
|---|---|---|
Market Cap | $5.07B | $505.73M |
Sector | Health | Health |
52-Week High | $29.41 | $16.14 |
52-Week Low | $20.06 | $5.48 |
Enterprise Value | $4.19B | $607.68M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
